MantaBio provides an automated molecular testing platform for rapid microbial detection in biopharmaceutical manufacturing. Their system delivers results in approximately two hours using qPCR technology, enabling faster, data-driven decisions and improving production efficiency.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional microbial contamination testing in biopharmaceutical manufacturing is time-consuming, relying on culture-based methods that can take days or weeks for results. This delay hinders efficient production workflows and increases the risk of significant product loss, manufacturing downtime, and financial impact due to contamination incidents.
Solution
MantaBio offers the MantaVision System, an automated molecular testing platform designed for rapid, sensitive microbial detection at the point-of-need. This system provides near-line screening capabilities, delivering results in approximately two hours, a significant reduction compared to conventional methods. By enabling faster, data-driven manufacturing decisions, MantaBio's technology supports the biopharmaceutical industry's transition towards Pharma 4.0 principles and real-time release. The system aims to improve manufacturing efficiency and product safety by identifying contaminants early in the production process.
Target Audience
The primary target audience includes biopharmaceutical manufacturers, R&D departments, Process Development teams, Analytical Development, Process Analytical Technologies (PAT), and Quality Assurance/Quality Control (QA/QC) units.
Features
- Automated, open-access molecular diagnostic system for pathogen detection.
- Utilizes quantitative Polymerase Chain Reaction (qPCR) technology for microbial identification.
- Capable of detecting up to 24 targets simultaneously, covering bacteria, fungi, mycoplasma, and common viruses.
- Achieves a sensitivity target of less than 10 colony forming units/milliliter (CFU/mL).
- Provides results in approximately 2 hours, with hands-on time under 1 minute.
- Features integrated sample preparation and automated run-time, including nucleic acid purification and PCR analysis.
- Delivers semi-quantitative PCR data with a digital readout, compatible with Laboratory Information Management Systems (LIMS).
- Designed for near-line use, with future development targeting at-line integration.
- Compliant with 21 CFR Part 11 regulations for data integrity.
- Utilizes disposable microfluidic consumables for sample processing.